Medidata and Techfields Launch mHealth Stroke Study

September 8, 2016

Leading China-Based Pharma Adopts Medidata’s Cloud and Mobile Health Technology to Gather More Objective Data

  NEW YORK, N.Y. and SHANGHAI, CHINA – Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, announced today that Techfields Pharma (“Techfields”) has selected the Medidata Clinical Cloud® to power a Phase II Ischemic Stroke study. The China-based pharmaceutical company will leverage Medidata’s robust study management capabilities and mobile health (mHealth) technology to optimize trial processes and gather new insights on treatment efficacy and patients’ quality of life.   “Cloud and mobile health technologies offer new channels for maximizing the value of clinical data, and we believe they will play an increasingly important role in our ability to bring vital new medicines to patients,” said Dr. Chongxi Yu, Techfields’ founder and president. “Using the Medidata platform, our research teams can more quickly access richer, more complete clinical datasets while gaining valuable insight into patient well-being and disease progression. This is a key focus of our R&D strategy, as we pursue promising drug candidates with the potential to help people live longer, healthier lives.”     Headquartered in Suzhou, China, Techfields is a leading clinical-stage pharmaceutical company focused on the development of novel medicines for inflammatory, autoimmune, cardiovascular, metabolic and aging-related diseases, as well as depression. To streamline trial operations and improve data quality in its upcoming Phase II Ischemic Stroke study, Techfields is adopting Medidata’s unified, cloud-based solutions for electronic data capture (Medidata Rave®), randomization and trial supply management (Medidata Balance®) and mHealth (Medidata Patient Cloud).   Medidata SensorLink is being used by Techfields to capture continuous data from the Garmin vívofit® 3 activity trackers measuring study participants’ movement and mobility. Techfields is also using Medidata’s Patient Cloud ePRO (electronic patient-reported outcome) app – easily accessible via a smartphone or tablet – to allow stroke patients participating in the trial to complete questionnaires on quality-of-life, disease state, and response to treatment using an Apple® iPad®. Data from the mHealth solutions is integrated into the secure, regulatory-compliant environment of the Medidata Clinical Cloud.   “Now more than ever, life sciences companies are evolving toward a more patient-centric approach to drug development and healthcare, and Medidata’s unified cloud platform, including our mHealth solutions, is helping to power that shift,” said Edwin Ng, Medidata’s vice president of field operations, APeJ (Asia Pacific except Japan). “We’re pleased to be Techfields’ technology partner, working with them to collect and interpret high volumes of in-life data in an objective and regulatory-compliant manner. Our team is excited to support a growing number of clients, like Techfields, whose efforts to more safely and quickly develop medicines are making a real difference in patients’ lives.”